# Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients

> **NCT03359850** · PHASE1 · COMPLETED · sponsor: **Tesaro, Inc.** · enrollment: 17 (actual)

## Conditions studied

- Ovarian Neoplasms
- Neoplasms
- Solid Tumor
- Hepatic Impairment

## Interventions

- **DRUG:** Niraparib

## Key facts

- **NCT ID:** NCT03359850
- **Lead sponsor:** Tesaro, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-20
- **Primary completion:** 2019-09-16
- **Final completion:** 2020-06-24
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2021-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03359850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03359850, "Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03359850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*